Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Gains from Investment Securities: 2020-2023

Historic Gains from Investment Securities for Candel Therapeutics (CADL) over the last 4 years, with Dec 2023 value amounting to $483,000.

  • Candel Therapeutics' Gains from Investment Securities rose 117.60% to $483,000 in Q4 2023 from the same period last year, while for Dec 2023 it was -$8.0 million, marking a year-over-year increase of 68.43%. This contributed to the annual value of $20.8 million for FY2024, which is 2253.42% up from last year.
  • Candel Therapeutics' Gains from Investment Securities amounted to $483,000 in Q4 2023, which was down 92.03% from $6.1 million recorded in Q3 2023.
  • In the past 5 years, Candel Therapeutics' Gains from Investment Securities ranged from a high of $8.2 million in Q3 2021 and a low of -$9.2 million during Q4 2021.
  • For the 3-year period, Candel Therapeutics' Gains from Investment Securities averaged around $530,991, with its median value being $380,000 (2021).
  • As far as peak fluctuations go, Candel Therapeutics' Gains from Investment Securities spiked by 28,348.28% in 2021, and later tumbled by 3,091.70% in 2022.
  • Candel Therapeutics' Gains from Investment Securities (Quarterly) stood at $4.5 million in 2020, then slumped by 303.32% to -$9.2 million in 2021, then spiked by 70.17% to -$2.7 million in 2022, then skyrocketed by 117.60% to $483,000 in 2023.
  • Its Gains from Investment Securities was $483,000 in Q4 2023, compared to $6.1 million in Q3 2023 and $6.4 million in Q2 2023.